Rybodyn
RyboDyn is a pioneering immunotherapy developer focused on unlocking the dark proteome using proprietary RyboCypher™ technology. They aim to transform hidden biological signals into breakthrough therapies, redefining patient care through next-generation immunotherapies. Their mission is to turn the secrets of the dark genome into actionable insights and first-in-class immunotherapies that revolutionize healthcare.
Industries
Nr. of Employees
small (1-50)
Products
Sequencing and AI proteogenomic discovery platform
Integrated platform that combines high-resolution RNA sequencing with machine learning models and curated proteomic datasets to detect cryptic RNAs and predict encoded proteins for target discovery.
Antibody-based immunotherapy candidates
Preclinical antibody drug candidates derived from discovered disease-specific targets designed for high specificity and reduced off-target effects, intended for advancement toward clinical development.
Sequencing and AI proteogenomic discovery platform
Integrated platform that combines high-resolution RNA sequencing with machine learning models and curated proteomic datasets to detect cryptic RNAs and predict encoded proteins for target discovery.
Antibody-based immunotherapy candidates
Preclinical antibody drug candidates derived from discovered disease-specific targets designed for high specificity and reduced off-target effects, intended for advancement toward clinical development.
Services
Target discovery and validation services
Discovery and experimental validation of disease-specific peptide and cell-surface targets derived from non-canonical transcripts, leveraging sequencing, proteomics, and clinical repository correlation.
Collaborative translational research
Partnership-driven projects that integrate discovery outputs with clinical tumor banks and metadata to accelerate translation of targets into therapeutic programs.
Target discovery and validation services
Discovery and experimental validation of disease-specific peptide and cell-surface targets derived from non-canonical transcripts, leveraging sequencing, proteomics, and clinical repository correlation.
Collaborative translational research
Partnership-driven projects that integrate discovery outputs with clinical tumor banks and metadata to accelerate translation of targets into therapeutic programs.
Expertise Areas
- Dark proteome and dark transcriptome discovery
- Proteogenomics
- AI-driven target identification
- Antibody-based immunotherapy development
Key Technologies
- High-resolution RNA sequencing
- Proteogenomic machine learning models
- Proprietary transcriptomic and proteomic databases
- Proteomic discovery workflows (peptide detection)